Brought to you by 
Abbott gets license to Seattle Genetics' ADC technology; deal expanded and AbbVie takes over
27 Apr 2018
Executive Summary
Seattle Genetics Inc. (antibody therapies for cancer and autoimmune disorders) has licensed Abbott Laboratories Inc. rights to use its antibody-drug conjugate (ADC) technology to identify antibodies against a single oncology target.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Abbott gets license to Seattle Genetics' ADC technology; deal expanded and AbbVie takes over
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice